Altered serum metabolomics in COPD: analysis of the SPIROMICS cohort

W. Labaki (Ann Arbor, United States of America), T. Gu (Ann Arbor, United States of America), S. Murray (Ann Arbor, United States of America), J. Curtis (Ann Arbor, United States of America), R. Bowler (Denver, United States of America), R. Barr (New York, United States of America), E. Hoffman (Iowa City, United States of America), A. Comellas (Iowa City, United States of America), N. Hansel (Baltimore, United States of America), C. Cooper (Los Angeles, United States of America), R. Kanner (Salt Lake City, United States of America), R. Paine Iii (Salt Lake City, United States of America), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, United States of America), M. Mcdonald (Birmingham, United States of America), J. Krishnan (Chicago, United States of America), E. Bleecker (Tucson, United States of America), S. Peters (Winston-Salem, United States of America), P. Woodruff (San Francisco, United States of America), W. O'Neal (Chapel Hill, United States of America), W. Diao (Beijing, China), B. He (Beijing, China), F. Martinez (New York, United States of America), T. Standiford (Ann Arbor, United States of America), K. Stringer (Ann Arbor, United States of America), M. Han (Ann Arbor, United States of America)

Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Session: COPD phenotypes: a1 antitrypsin deficiency and beyond
Session type: Poster Discussion
Number: 580
Disease area: Airway diseases

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Labaki (Ann Arbor, United States of America), T. Gu (Ann Arbor, United States of America), S. Murray (Ann Arbor, United States of America), J. Curtis (Ann Arbor, United States of America), R. Bowler (Denver, United States of America), R. Barr (New York, United States of America), E. Hoffman (Iowa City, United States of America), A. Comellas (Iowa City, United States of America), N. Hansel (Baltimore, United States of America), C. Cooper (Los Angeles, United States of America), R. Kanner (Salt Lake City, United States of America), R. Paine Iii (Salt Lake City, United States of America), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, United States of America), M. Mcdonald (Birmingham, United States of America), J. Krishnan (Chicago, United States of America), E. Bleecker (Tucson, United States of America), S. Peters (Winston-Salem, United States of America), P. Woodruff (San Francisco, United States of America), W. O'Neal (Chapel Hill, United States of America), W. Diao (Beijing, China), B. He (Beijing, China), F. Martinez (New York, United States of America), T. Standiford (Ann Arbor, United States of America), K. Stringer (Ann Arbor, United States of America), M. Han (Ann Arbor, United States of America). Altered serum metabolomics in COPD: analysis of the SPIROMICS cohort. 580

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: